Early effect of hepatic artery TNF-α infusion on systemic hemodynamics and inflammation: A dose-response study in pigs

International Journal of Colorectal Disease

Volumn 25, Issue 4, 2010, Pages 523-532

  Schäfer, Thilo ^a   Sperling, Jens ^a   Kollmar, Otto ^a   Richter, Sven ^a   Schilling, Martin K ^a   Menger, Michael D ^a   Lindemann, Werner ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Colorectal cancer; Hepatic artery infusion; Hepatic tumors; Metastasis; PiCCO; Pigs; Side effects; Systemic hemodynamics; TNF regional chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CARBON DIOXIDE; CREATINE KINASE; CREATINE KINASE MB; GLUTAMATE DEHYDROGENASE; HETASTARCH; LACTATE DEHYDROGENASE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING; CARBON DIOXIDE TENSION; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; HEART PRELOAD; HEART RATE; HEMODYNAMIC PARAMETERS; HEPATIC ARTERY; LIVER CELL CARCINOMA; LIVER PERFUSION; LIVER TOXICITY; LUNG TOXICITY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC ACIDOSIS; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HEMODYNAMICS; HEPATIC ARTERY; HETASTARCH; INFLAMMATION; INFUSIONS, INTRA-ARTERIAL; SWINE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR RESISTANCE;

EID: 77953288874     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0827-7     Document Type: Article

References (45)

1. Ku Y, Tominaga M, Iwasaki T, Fukumoto T, Kuroda Y (2002) Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. Int J Clin Oncol 7:82-90
2. Liver Cancer Study Group of Japan (1994) Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74:2772-2780
3. Choi TK, Edward CS, Fan ST, Francis PT, Wong J (1990) Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 37:172-175
4. Nagasue N (1998) Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg 5:7-13
5. Rougier P (1998) Are there indications for intraarterial hepatic chemotherapy or isolated liver perfusion? The case of liver metastases from colorectal cancer. Recent Results Cancer Res 147:3-12
6. Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J (2000) Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 191:381-388
7. Pichlmayr R, Ringe B, Bechstein WO, Lauchart W, Neuhaus P (1988) Approach to primary liver cancer. Recent Results Cancer Res 110:65-73
8. Mok KT, Wang BW, Lo GH, Liang HL, Liu SI, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC (2003) Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surg 197:730-738
9. Lai CL, Yuen MF (2007) The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 147:58-61
10. Yeh CN, Chen MF (2004) Resection of peritoneal implantation of hepatocellular carcinoma after hepatic resection: risk factors and prognostic analysis. World J Surg 28:382-386
11. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M (2007) Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141:196-202
12. Lee CS, Sung JL, Hwang LY, Sheu JC, Chen DS, Lin TY, Beasley RP (1986) Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma. Surgery 99:481-490
13. Bilchik AJ, Wood TF, Allegra D, Tsioulias GJ, Chung M, Rose DM, Ramming KP, Morton DL (2000) Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 135:657-662
14. Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, Granchi J, Curley SA (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592-599
15. Christians KK, Pitt HA, Rilling WS, Franco J, Quiroz FA, Adams MB, Wallace JR, Quebbeman EJ (2001) Hepatocellular carcinoma: multimodality management. Surgery 130:554-559
16. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P (2000) Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232:381-391
17. Yamanaka N, Tanaka T, Oriyama T, Furukawa K, Tanaka W, Okamoto E (1996) Microwave coagulonecrotic therapy for hepatocellular carcinoma. World J Surg 20:1076-1081
18. Hamazoe R, Hirooka Y, Ohtani S, Katoh T, Kaibara N (1994) Intraoperative microwave tissue coagulation as treatment for patients with nonresectable hepatocellular carcinoma. Cancer 75:794-800
19. Amin Z, Donald JJ, Masters A, Kant R, Steger AC, Bown SG, Lees WR (1993) Hepatic metastases: interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology 187:339-347
20. Hill CR, ter Haar GR (1995) Review article: high intensity focused ultrasound - potential for cancer treatment. Br J Radiol 68:1296-1303
21. Liao CS, Yang KC, Yen AM, Chen LS, Chen TH (2006) Remission, relapse, and metastasis/death of small hepatocellular carcinoma treated with percutaneous ethanol injection. Cancer J 12:194-200
22. Cho YB, Lee KU, Suh KS, Kim YJ, Yoon JH, Lee HS, Hahn S, Park BJ (2007) Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching. J Gastroenterol Hepatol 22:1643-1649
23. Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16:1479-1489
24. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR (2001) Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129:176-187
25. DeVries MR, Borel Rinkes IHM, Buurman WA (1995) Soluble TNF-α receptor induction by isolated hepatic perfusion with TNF-α and melphalan. Eur Surg Res 27:108
26. Lin G, Lunderquist A, Hägerstrand I, Boijsen E (1984) Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 96:517-526
27. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM (1987) Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer 59:1547-1553
28. Kollmar O, Richter S, Czyborra J, Menger MD, Dietrich S, Schilling MK, Kirsch CM, Pistorius GA (2004) Aprotinin inhibits local platelet trapping and improves tissue destruction in hepatic cryosurgery. Surgery 136:624-632
29. Bajorat J, Hofmockel R, Vagts DA, Janda M, Pohl B, Beck C, Noeldge-Schomburg G (2006) Comparison of invasive and lessinvasive techniques of cardiac output measurement under different haemodynamic conditions in a pig model. Eur J Anaesthesiol 23:23-30
30. Hofer CK, Furrer L, Matter-Ensner S, Maloigne M, Klaghofer R, Genoni M, Zollinger A (2005) Volumetric preload measurement by thermodilution: a comparison with transoesophageal echocardiography. Br J Anaesth 94:748-755
31. Creasey AA, Reynolds MT, Laird W (1986) Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 46:5687-5690
32. Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989
33. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU (1988) A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 6:1328-1334
34. Whitehead RP, Fleming T, Macdonald JS, Goodman PJ, Neefe J, Braun TJ, Swinnen LJ, Hersh EM (1990) A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. J Biol Response Modif 9:588-591
35. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR (2001) Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129:176-187
36. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224:756-764
37. Grover A, Alexander HR Jr (2004) The past decade of experience with isolated hepatic perfusion. Oncologist 9:653-664
38. Lejeune FJ, Liénard D, Matter M, Rüegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6
39. van Etten B, de Vries MR, van IJken MG, Lans TE, Guetens G, Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL (2003) Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 88:314-319
40. Wang P, Ayala A, Ba ZF, Zhou M, Perrin MM, Chaudry IH (1993) Tumor necrosis factor-alpha produces hepatocellular dysfunction despite normal cardiac output and hepatic microcirculation. Am J Physiol 265:G126-G132
41. Vrouenraets BC, Kroon BB, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJ, Eggermont AM (1993) Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 6:405-412
42. Larrick JW, Graham D, Toy K, Lin LS, Senyk G, Fendly BM (1987) Recombinant tumor necrosis factor causes activation of human granulocytes. Blood 69:640-644
43. Mukhopadhyay S, Hoidal JR, Mukherjee TK (2006) Role of TNFalpha in pulmonary pathophysiology. Respir Res 7:125
44. Worrall NK, Chang K, LeJeune WS, Misko TP, Sullivan PM, Ferguson TB Jr, Williamson JR (1997) TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and-independent mechanisms. Am J Physiol 273: H2565-H2574
45. Laurenzi L, Natoli S, Di Filippo F, Calamaro A, Centulio F, Anzà M, Cavaliere F, Marcelli ME, Garinei R, Arcuri E (2004) Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J Exp Clin Cancer Res 23:225-231